Paul Andrew Moore - 18 Jul 2022 Form 4 Insider Report for Zymeworks Inc.

Role
Chief Scientific Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
18 Jul 2022
Net transactions value
$0
Form type
4
Filing time
19 Jul 2022, 21:05:15 UTC
Next filing
06 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +200,000 $0.000000 200,000 18 Jul 2022 Common Shares 200,000 $5.82 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.